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Text S1: Supplementary Methods 
 
 
 
Search criterion 
 
PubMed search string 
 
PubMed MeSH search 
(1) "tamoxifen"[MeSH Terms]; (2) "cytochromes"[MeSH Terms]; (3) 
"cytochrome p 450 enzyme system"[MeSH Terms]; (4) "hydroxylation"[MeSH 
Terms]; (5) "imipramine"[MeSH Terms]; (6) "sparteine"[MeSH Terms]; (7) 
"oxygenases"[MeSH Terms]; (8) "cell proliferation"[MeSH Terms]; (9) 2 OR 3 
OR 4 OR 5 OR 6 OR 7 OR 8; (10) "genotype"[MeSH Terms]; (11) 
"genes"[MeSH Terms]; (12) "genetic association studies"[MeSH Terms]; (13) 
"alleles"[MeSH Terms]; (14) "polymorphism, genetic"[MeSH Terms]; (15) 
"polymorphism, single nucleotide"[MeSH Terms]; (16) 10 OR 11 OR 12 OR 
13 OR 14 OR 15; (17) 1 AND 9 AND 16 
 
PubMed text word search 
(1) tamoxifen OR ICI-46,474 OR ICI-46474 OR ICI-47699 OR Nolvadex OR 
Novaldex OR Soltamox OR Tamoxifen Citrate OR Tomaxithen OR Zitazonium; 
(2) "Valodex"; (3) "Istubal"; (4) N-desmethyl tamoxifen; (5) 4-
hydroxytamoxifen; (6) endoxifen; (7) 1 OR 2 OR 3 OR 4 OR 5 OR 6; (8) 
Cytochrome*; (9) Cytochrome-P450*; (10) Cytochrome P450; (11) 
Cytochrome P-450 OR Cytochrome P-450 Monooxygenase OR Cytochrome 
P-450 Oxygenase OR Cytochrome P-450-Dependent Monooxygenase; (12) 
CYP2D6*; (13) Cytochrome P450 2D6 OR Debrisoquine 4-Hydroxylase OR 
Debrisoquine 4-Monooxygenase OR Debrisoquine Hydroxylase OR 
Imipramine 2-Hydroxylase OR Sparteine Monooxygenase; (14) 8 OR 9 OR 10 
OR 11 OR 12 OR 13; (15) Genotyp*; (16) Gene; (17) Allele*; (18) 
Polymorphism*; (19) 15 OR 16 OR 17 OR 18; (20) 7 AND 14 AND 19 
 
 
EMBASE search string 
 
EMBASE subject heading search 
(1) exp tamoxifen/; (2) exp tamoxifen citrate/; (3) 1 OR 2; (4) exp cytochrome/; 
(5) exp cytochrome P450/; (6) exp oxygenase/; (7) exp cytochrome P450 2D/; 
(8) exp cytochrome P450 2D6/; (9) exp debrisoquine 4 hydroxylase/; (10) exp 
2 hydroxyimipramine/; (11) exp 4' hydroxytamoxifen/; (12) 4 OR 5 OR 6 OR 7 
OR 8 OR 9 OR 10 OR 11; (13) exp genotype/; (14) exp genotype phenotype 
correlation/; (15) exp gene/; (16) exp genetic association/; (17) exp allele/; (18) 
exp genetic polymorphism/; (19) 13 OR 14 OR 15 OR 16 OR 17 OR 18; (20) 
3 AND 12 AND 19 
 
EMBASE text word search 
(1) (tamoxifen or ICI-46,474 or ICI-46474 or ICI-47699 or Nolvadex or 
Novaldex or Soltamox or Tamoxifen Citrate or Tomaxithen or Zitazonium).af.; 
(2) Valodex.mp.; (3) Istubal.mp.; (4) N-desmethyl tamoxifen.mp.; (5) 4-
 2 
hydroxytamoxifen.mp.; (6) endoxifen.mp.; (7) 1 or 2 or 3 or 4 or 5 or 6; (8) 
Cytochrome$.mp.; (9) Cytochrome-P450$.mp.; (10) Cytochrome P450.mp.; 
(11) (Cytochrome P-450 or Cytochrome P-450 Monooxygenase or 
Cytochrome P-450 Oxygenase or Cytochrome P-450-Dependent 
Monooxygenase).af.; (12) CYP2D6$.mp.; (13) (Cytochrome P450 2D6 or 
Debrisoquine 4-Hydroxylase or Debrisoquine 4-Monooxygenase or 
Debrisoquine Hydroxylase or Imipramine 2-Hydroxylase or Sparteine 
Monooxygenase).af.; (14) 8 or 9 or 10 or 11 or 12 or 13; (15) Genotyp$.mp.; 
(16) Gene$.mp.; (17) Allele$.mp.; (18) Polymorphism$.mp.; (19) 15 or 16 or 
17 or 18; (20) 7 and 14 and 19 
 
In addition, the full text articles of two randomized clinical trials (the ATAC and 
the BIG 1-98 clinical trials) that initially presented their results in abstract form 
at the 2010 San Antonio Breast Cancer Symposium (SABCS) were 
included.[1,2] 
 
 
Grouping of CYP2D6 alleles for the investigation of dose-response 
relationship (one or two versus no reduced function CYP2D6 alleles) 
 
For the ‘one reduced function CYP2D6 allele versus none’ comparison, 
studies that reported individuals with one copy of a reduced function or non-
functional CYP2D6 allele were compared to the reference wildtype (*1/*1). 
The corresponding categorisation for the predicted phenotype studies was IM 
status (including heterozygous extensive metabolizer [hetEM] and 
heterozygous intermediate metabolizer [hetIM]) versus EM/UM phenotype. 
For the ‘two reduced function CYP2D6 alleles versus none’ comparison, 
studies that reported individuals with two copies of a reduced function and/or 
non-functional allele were compared to the reference wild-type (*1/*1). The 
corresponding categorisation for the predicted phenotype studies was PM 
status versus EM/UM phenotype. 
 
 
Subgroup analyses 
 
Subgroups were defined based on the following baseline clinical and 
methodological characteristics: 
 
i. Study characteristics comprised of design [case-control, cohort, 
randomized-controlled trial (RCT)], number of enrolled participants, 
number of clinical events, duration of follow-up, loss to follow-up, 
genotype ascertainment with outcome blinded, outcome ascertainment 
with genotype blinded, and matching features (for case-control studies 
only). 
 
ii. Participant characteristics comprised of ethnicity, age and menopause 
status (pre-, peri- or post-menopause). 
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iii. Genotype characteristics comprised of genotype platform, genotype 
call rate, whether the CYP2D6 alleles genotyped were in Hardy-
Weinberg equilibrium (HWE), and the genotypes (whether single or 
grouped) compared. 
 
iv. Treatment characteristics comprised of concordance to tamoxifen, and 
whether tamoxifen was administered as a monotherapy or given with 
concomitant drugs. 
 
v. Breast cancer characteristics comprised of breast cancer type (primary, 
metastatic or others), grade (1, 2 or 3) and stage (I, II, III or IV), lymph 
node involvement, tumour size, estrogen receptor (ER) and 
progesterone receptor (PR) statuses. 
 
vi.  Reported data characteristics comprised of type of data (raw event 
counts, hazard ratio, odds ratio or rate ratios) and whether the 
summary estimates (if any) were adjusted for clinical and/or other 
factors. 
 
 
We used the Chi-square statistic from the ‘metan’ command in Stata 11.2 
(StataCorp, College Station, Texas, USA) to test for differences between 
subgroups. 
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